Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 15, 2000

View Archived Issues

Abacavir/mycophenolic acid combination active against multidrug-resistant HIV-1

Ixsys announces name change

Millennium uncovers role of Madh6 gene in cardiovascular defects

Cambridge Antibody Technology reports progress in 1999

Exelixis delivers target for screening to Pharmacia & Upjohn

HSL disruption produces sterility without obesity

Ophthalmic antibacterial on the way to market in Japan

Plan B receives Canadian approval for postcoital contraception

Biovail acquires Canadian marketing rights for Ampligen

Clinical testing continues with Snow Brand's erythropoietin

Solvay receives marketing exclusivity extension from FDA for Luvox

Lymphoma therapeutic from Immunomedics gives positive phase I results

Avax Technologies updates AC vaccine progress

New artemisinin derivatives from Hong Kong active against sensitive and resistant malarial strains

Synthesis and use of new PKC inhibitors in development at AstraZeneca

Novel Merck compounds inhibit KDR kinase and VEGF activity

First market introduction for INOmax

Potent and selective ETA antagonist selected as development candidate

Neuroprotection provided by new compounds synthesized at Monash University

Neurokinin antagonists in early development at AstraZeneca

Neuroprotective and antiapoptotic effects of ebselen in mice with striatal ischemic injury

Antipsoriatic activity of EGF receptor tyrosine kinase inhibitor SU-5271

Sustiva granted traditional FDA approval based on duration of treatment response

Neuroprotective effects of p38 MAP kinase inhibition confirmed in stroke model

Bio-Technology General obtains first marketing approval worldwide for HBV vaccine

FDA extends decision date for Novastan NDA to Feburary 18

Stroke conference news: PD-98059 effective in cerebral vasospasm in dogs

Humanized anti-E/P-selectin MAb from PDL shows promise as stroke Rx